^
    Apply
    JY025 is a First-line Treatment for EGFR Mutated NSCLC Phase II and III Clinical Trials of Efficacy and Safety (NCT04874844)
    Phase 2/3
    Beijing Dongfang Biotech Co., Ltd.
    Not yet recruiting
    Last update posted :
    05/10/2021
    Initiation :
    07/30/2021
    Primary completion :
    03/30/2022
    Completion :
    06/30/2023
    EGFR
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    erlotinib • gefitinib • JY025